https://www.selleckchem.com/pr....oducts/6-aminonicoti
5, P=.045), compared to stable neurotoxicity in the veliparib arm (M difference=-0.2, P=.778). Weakness was the most common treatment-emergent (50%) and moderate to severe (16%) symptom reported, but did not differ between treatment arms. The proportion of adherence to oral therapy in the overall sample was 75%. Three percent of patients reported clinically significant neurotoxicity that was not captured by physician assessment. Neurotoxicity scores were not different between treatment arms. The addition of veliparib
Like
Comment
Share
